ERBB2 and breast neoplasm: Another co-module (#5) was related to human epidermal growth factor receptor 2 (HER2)-activated breast tumours, which was enriched with the features of HER2 amplification, overexpression, and breast tumour, and also showed sensitivity to the HER2 inhibitor lapatinib (Fig. 3b).